Kornimate/medical-research-clean huggingface dataset:
the efficacy of isocapnic hyperpnoea to accelerate recovery after general anesthesia with sevoflurane

Conditions: Anesthesia

Summary: the twilight phase between being asleep and awake during recovery from anesthesia is a precarious time fraught with risks to the post-operative patient. hyperventilation accelerates the elimination of inhaled anesthetics but reduces their co2 blood concentrations which delays their resumption of spontaneous breathing. we previously showed that our method of hyperventilation without affecting the co2 concentration--which we call ih--accelerates the rate of emergence from anesthesia with isoflurane. in this study we will study the effect of ih on the rate of emergence from sevoflurane anesthesia.


Eligibility criteria:
inclusion criteria: 1. elective gynecological procedure 2. asa i-iii 3. age 18-80 years 4. signed informed consent exclusion criteria: 1. asa iv 2. patients with contra-indications to sevoflurane anesthesia or other anesthetics included in the protocol 3. active smoking, asthma or other history of hyper-reactive airway disease 4. history of chronic obstructive lung disease limiting exercise 5. history of angina, previous myocardial infarction, valvular heart disease, or heart surgery 6. presence of heart murmurs or neck bruits 7. ect abnormalities including atrial fibrillation, prolonged p-r interval, prolonged q-t interval, presence of q waves in inferior, anterior or lateral leads, criteria for left ventricular hypertrophy, t-wave abnormalities, 8. history of difficult airway access 9. pulmonary hypertension and/or right ventricle dysfunction 10. history of bulous emphysema, and/or spontaneous pneumothorax 11. history of alcohol or drugs abuse 12. known history of psychiatric illness and/or medications 13. patients that required postoperative mechanical ventilation for any reason

Keywords: general anesthesia, hyperventilation, carbon dioxide, isocapnic hyperponea
a retrospective study of anti-vascular endothelial growth factor (vegf) injections for retinal vein occlusion or diabetic macular edema

Conditions: Retinal Vein Occlusion; Macular Edema

Summary: this retrospective data review study will evaluate anti-vegf injections for retinal vein occlusion (rvo) or diabetic macular edema (dme).


Eligibility criteria:
inclusion criteria: * macular edema in the study eye due to rvo or dme * received an anti-vegf injection in the study eye on or after june 2010 for rvo and on or after august 2012 for dme exclusion criteria: * none
catheter-directed venous thrombolysis in acute iliofemoral vein thrombosis

Conditions: Deep Vein Thrombosis

Summary: deep vein thrombosis (dvt) is a severe disease, and conventional treatment with low molecular weight heparin (lmwh) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (pts). catheter-directed thrombolytic (cdt) therapy has been introduced worldwide the last two decades. reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. this multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or cdt in addition to conventional treatment. main outcome parameters are patency rates at 6 months and prevalence of pts at 24 months. the main short-term hypothesis is that cdt of first-time acute dvt will increase patency of the affected segments after 6 months from \ 80%. the main long-term hypothesis is that cdt will improve long-term functional outcome, i.e. risk of pts after 2 years from \>25% to \<10%.


Eligibility criteria:
inclusion criteria: * onset of symptoms \<21 days * objectively verified dvt of the femoral or common iliac veins or the combined iliofemoral segment * informed consent exclusion criteria: * anticoagulant therapy prior to trial entry \>7 days * contraindications to thrombolytic therapy * indications for thrombolytic therapy, i.e. phlegmasia coerulea dolens or vena cava thrombosis * severe anemia, hemoglobin (hgb)\<8 g/dl * thrombocytopenia, platelets \<80x10\^9/l * severe renal failure, creatinine clearance \<30ml/min * severe hypertension, systolic (syst) blood pressure (bp)\>160 mmhg or diastolic (diast) bp \>100 mmhg pregnancy * less than 14 days post-surgery or post-trauma * history of subarachnoidal or intracerebral bleeding * disease with life expectancy \<24 months * drug abuse or mental disease that may interfere with treatment and follow-up * former ipsilateral proximal dvt * chemotherapy or advanced malignant disease

Keywords: thrombolytic therapy postphlebitic syndrome venous thrombosis
ketogenic diet drink study

Conditions: Intractable Epilepsy

Summary: an evaluation of the tolerance, compliance, acceptability and safety of a nutritionally complete liquid feed for use as part of the ketogenic diet (kd) in children 8+ years, adolescents and adults with intractable epilepsy or other disorders where the kd is indicated.

an evaluation of the tolerance, compliance, acceptability and safety of a nutritionally complete liquid feed for use as part of the ketogenic diet (kd) in children 8+ years, adolescents and adults with intractable epilepsy or other disorders where the kd is indicated. study is conducted over 59 days: 3 day baseline period - patient continues on whatever dietary regimen they were on before joining the study (this may be a ketogenic diet for existing patients). 28 day control period - patient begins ketogenic diet (if they are not already on one), and continues this for 28 days without the study product. patients already on a ketogenic diet continue this as normal. 28 day intervention period - a set amount of the study product is incorporated into the patient's ketogenic diet. data is captured by the hcp in the case report form at baseline, mid study and end of intervention, and by the patient daily throughout in a patient questionnaire.

Eligibility criteria:
inclusion criteria: * male or female * 8 years of age or older * diagnosed with intractable epilepsy or another disorder where the kd is indicated * motivated to follow the kd for at least the duration of the trial period * either currently on a kd, or referred to start a kd * likely to benefit from ketocal 2.5:1 * written informed consent from patient and/or parent/carer, or completed consultee declaration form * willing to take finger prick blood samples to measure ketone levels exclusion criteria: * being pregnant or planning pregnancy * requiring parenteral nutrition * major hepatic or renal dysfunction * participation in other clinical intervention studies within 1 month prior to entry of this study * allergy to any of the study product ingredients * investigator concern around willingness/ability of patient or parent/carer to comply with protocol requirements * any contraindications for the use of the ketogenic diet * significantly underweight (body mass index \<18.5)
a single-center prospective cohort study for pure pulmonary ground glass nodules in women preparing for pregnancy

Conditions: Lung Cancer

Summary: in this study, about 200 pure ggo in women preparing for pregnancy will be included for a 5-year follow-up. the aim of this study is to elucidate the biological nature of pulmonary ggo lesion in women preparing for pregnancy and provide evidence for ggo treatment.


Eligibility criteria:
inclusion criteria: - 20-45 years' old found pulmonary ggo with chest ct scan and ct follow-up after 3 months shows that the ggo remains diameter of ggo \> 5mm and \< 3cm exclusion criteria: - receiving immunosuppressor or steriods receiving chemo- or radio- therapy can not receive regular follow-up
oscillation mechanics of the respiratory system in never-smoking patients with silicosis

Conditions: Silicosis

Summary: silicosis is a chronic and incurable occupational disease that can progress independent of the end of exposure. recent works suggest that the forced oscillation technique (fot) may help to improve our understanding of the changes in lung mechanics, as well as in the detection of these changes. objectives: analyze the effects of airway obstruction in silicosis on the respiratory impedance and evaluated the diagnostic use of the fot in these patients. for this, the investigators used spirometry to classify airway obstruction, which resulted in four categories: control, patients with normal exam, mild obstruction, and moderate-to-severe obstruction. resistive data were interpreted using the zero-intercept resistance (r0), the resistance at 4 hz (rrs4) and the mean resistance (rm). the investigators also analyzed the mean reactance (xm) and the dynamic compliance (crs,dyn). the total mechanical load was evaluated using the absolute value of the respiratory impedance (z4hz). the diagnostic potential was evaluated by investigating the area under the receiver operating characteristic curve (auc).


Eligibility criteria:
inclusion criteria: * • volunteers with silicosis for patients group; * volunteers without any respiratory disease for the control group. exclusion criteria: * smokers

Keywords: silicosis forced oscillations respiratory mechanics
the sccs polypill pilot trial

Conditions: Hypertension; Hyperlipidemia

Summary: in this study the investigators will examine the effect of the polypill on medication adherence, systolic blood pressure, and ldl cholesterol over a 12 month span.

the purpose of this study is to assess if a polypill-based approach to primary cvd prevention is feasible in a low socioeconomic status population. the study will assess whether a polypill approach is associated with better cardiovascular risk factor control compared with usual care. the polypill will be supplied as a compounded pill containing atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg. the medications in the polypill have been extensively evaluated individually and in combination. each of the medications in the polypill is approved by the united states food and drug administration (fda) and widely administered in the us for the treatment of and prevention of cardiovascular disease. the doses of each component medication included in the polypill are low, which should minimize the chance of any potential side-effects. in this study we assess medication adherence, systolic blood pressure, and ldl cholesterol over a 12 month span, in subjects taking the polypill versus subjects under usual care.

Eligibility criteria:
inclusion criteria: * enrolled at the sccs site in mobile, alabama, obtain care at franklin primary health center, or live in the surrounding area. * aged 45-75 years * baseline systolic blood pressure ≥120 mm hg. in this open-label trial, the study physicians are permitted to prescribe any additional medication deemed appropriate to achieve blood pressure control. exclusion criteria: * history of coronary heart disease or stroke * history of cancer, except for basal cell skin cancer * history of liver disease, not including chronic, clinically-stable hepatitis * laboratory evidence of hepatic dysfunction (an alanine aminotransferase level more than two times the upper limit of the normal range) * known renal disease, estimated creatinine clearance \< 60 * current use of more than 2 anti-hypertensive medications * ldl cholesterol ≥190 mg/dl * insulin-dependent diabetes * known intolerance to any of the components of the polypill * potassium \ 5.5 meq/l * use of medications that interact with statins, including those affecting the cytochrome p450 system * current use of diuretics for indications other than hypertension * comorbidities that might be expected to limit lifespan during the 12-month follow-up period * inability to provide consent.

Keywords: combination pill polypill primary prevention
a clinical study to evaluate the safety and effectiveness of the rxsight light adjustable lens (lal) in subjects desiring an extended depth of focus

Conditions: Aphakia; Cataract; Presbyopia

Summary: the primary objective of this study is to evaluate, for the visual correction of aphakia and presbyopia, the safety and effectiveness of the rxsight light adjustable lens (lal) to provide an extended depth of focus (improve intermediate and near visual acuity without compromising distance visual acuity) in subjects who have undergone bilateral implantation with the lal and subsequent light treatments for refractive and presbyopia correction (lal group).


Eligibility criteria:
inclusion criteria: * must sign a written informed consent form and be willing to undergo cataract surgery for the bilateral implantation of either the lal or sofport li61ao intraocular lens (iol) (bausch + lomb). * must be willing to be randomized to either the lal group (bilaterally implanted with the lal and receive light treatments for refractive and presbyopia correction) or the control group * between the ages of 40 and 80 inclusive on the day the cataract surgery is performed. * cataractous lens changes as demonstrated by best corrected distance visual acuity (bcdva) of 20/40 or worse with or without a glare source in both eyes. * willing and able to comply with the requirements for study specific procedures and visits. * able to complete a written questionnaire in english. exclusion criteria: * pre-existing macular disease in either eye. * patient with sufficiently dense cataract that precludes examination of the macula in either eye. * diabetes with any evidence of retinopathy in either eye. * evidence of glaucomatous optic neuropathy in either eye. * history of uveitis in either eye. * keratoconus or suspected of having keratoconus in either eye. * has undergone previous corneal or intraocular surgery in either eye, except eyes with previous pterygium excision are permitted as long as the pterygium did not extend more than 2mm onto the cornea from the limbus. * subjects taking systemic medication that may increase sensitivity to uv light such as tetracycline, doxycycline, psoralens, amiodarone, phenothiazines, chloroquine, hydrochlorothiazide, hypericin, ketoprofen, piroxicam, lomefloxacin, and methoxsalen. ldd treatment in patients taking such medications may lead to irreversible phototoxic damage to the eye. this is only a partial list of photosensitizing medications. please evaluate all medications that the patient is taking for this effect prior to consideration for implantation. * subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen. * history of ocular herpes simplex virus in either eye. * subject who has participated within another ophthalmic clinical trial within the last 3 months.

Keywords: light adjustable lens intraocular lens lal
characteristics of eosinophilic gastritis, enteritis, and colitis in a multi-site cohort

Conditions: Eosinophilic Esophagitis; Eosinophilic Gastritis; Eosinophilic Gastroenteritis; Eosinophilic Colitis

Summary: the purpose of this study is to investigate features of patients with eosinophilic gastrointestinal disorders (egids) other than eosinophilic esophagitis (eoe) alone, including eosinophilic gastritis (eg), eosinophilic gastroenteritis (ege), and eosinophilic colitis (ec).

this retrospective chart review study will analyze the demographics, medical history, clinical features, and pathological data of patients with eosinophilic gastrointestinal disorders (egids) other than eosinophilic esophagitis (eoe) alone, including eosinophilic gastritis (eg), eosinophilic gastroenteritis (ege), and eosinophilic colitis (ec).

Eligibility criteria:
inclusion criteria: * diagnosis of an egid including eg, ege, and/or ec. subjects with eoe can be included if they also have another egid. * clinical symptoms of gastrointestinal dysfunction. * findings of increased eosinophils on tissue biopsy at the time of diagnosis, before treatment initiated. * exclusion of other causes of gastrointestinal eosinophilia. exclusion criteria: * gastrointestinal eosinophilia caused by another disorder. * diagnosis of eoe without another egid. * insufficient medical record or pathology data available to support an egid diagnosis.

Keywords: eosinophilic gastrointestinal disorders
evaluation of the hypoallergenicity of a new formula based on hydrolyzed rice proteins

Conditions: Cow Milk Allergy

Summary: the aim of this study is to show the hypoallergenicity of a new thickened rice based formula (trhf) through a double blind placebo controlled food challenge (dbpcfc), as recommended by the american academy of pediatrics, in subjects with ige-mediated cma and in subjects with non-ige-mediated cma.

the study is made of 2 different steps : 1st step is a double blind randomised food challenge where the new formula is compared to a placebo. the second part of the trial consists in an open phase during which all infants will be fed with the study formula.

Eligibility criteria:
inclusion criteria: * with suspected cma or with a cma diagnosed by a dbpcfc performed in the last 2 months prior to inclusion * free of clinical allergic symptoms for at least one week (i.e. successfully fed an elimination diet); * whose parents signed the informed consent exclusion criteria: * mainly breast fed, drinking less than 250ml of formula/day, presenting any situation, which, according to the investigator, may interfere with the study participation or lead to a particular risk for the subject
a phase 3 clinical trial to evaluate the efficacy and safety of vsa003 in chinese hofh patients

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)

Summary: significant reduction in angplt3 levels is expected to reduce plasma ldl-c and tg levels and may lead to the reduction of risk of coronary heart disease and cardiovascular events associated with hypertriglyceridemia and ldl-c in subjects with persistent dyslipidemia. in this clinical study, the efficacy and safety of vsa003, an rnai-based therapeutic targeting angptl3, will be evaluated in subjects with hofh.


Eligibility criteria:
inclusion criteria: * male or female aged ≥ 12 years and weighing ≥ 40 kg at the time of icf signature; * patients with hofh who meet genetic or clinical diagnosis; * willing to follow a daily low-fat diet for the duration of the study; * receiving stable and tolerable lipid-lowering therapy prior to ldl-c testing during the screening period; * fasting ldl-c ≥ 2.6 mmol/l. exclusion criteria: * have received or are receiving targeted angptl3 treatment within 5 months or 5 half-lives, whichever is longer, prior to screening; * fasting tg ≥ 4.5 mmol/l at screening; * presence of uncontrolled endocrine disease affecting lipids or lipoproteins; * weight change of more than 10% in the 4 weeks prior to randomisation; * initiation of a new dietary plan or significant differences from previous dietary structure and habits within 4 weeks prior to screening; * women who are pregnant (including planned pregnancies) or breastfeeding; * refusal to limit alcohol consumption to moderate limits and below during the study period, specifically no more than 14 units per week; * uncontrolled hypertension (blood pressure \> 160/100 mmhg at screening); * new york heart association (nyha) class iv heart failure or left ventricular ejection fraction \<30% within 12 months prior to screening; * history of major surgery within 12 weeks prior to baseline, or planning to undergo major surgery during the study; * known allergy to any component of the study drug.
quantitative eeg markers in mild cognitive impairment in epilepsy

Conditions: Epilepsy

Summary: epileptic patients are plighted with limited daily activities, social dysfunction, family conflicts and cognitive impairment. most of the studies had showed that cognitive disorders were frequent in patients with epilepsy.the cognitive impairment has been reported in around 25% of epileptic patients.

cognitive consequences in epilepsy are often described in the following domains: verbal memory, language, executive functions, and attention. however, most of the studies focus on one or two domains in a relatively small sample. few studies have investigated the influential factors for the epilepsy-related cognitive impairment . however, most of these studies merely focused on one or a few potential factors and failed to consider possible distractions from other influential factors. therefore, it is crucial to include more potential factors in the analysis and to rule out possible confounding interactions between factors.

Eligibility criteria:
inclusion criteria: * patients with clinically confirmed epilepsy in adult patients. * non-symptomatic epilepsy. * normal ct or mri brain, and * education level of primary school at least to respond to the scales correctly were included. exclusion criteria: * psycho-neurological illnesses, * history of alcoholism or drug abuse, or * recently on medications that may affect cognitive functions (like antidepressants and antipsychotic drugs).

Keywords: epilepsy, mini mental state examination
extended depth of focus contact lenses for presbyopia

Conditions: Presbyopia

Summary: vti has an fda cleared soft contact lens product. its optical design creates an enhanced depth of focus (edof), which provides clear distance, intermediate, and near vision. this study is to quantify the enhanced depth of focus and visual impact.

this study will develop defocus curves for baseline best corrected spectacle refraction and then for the edof lens used in this study. a comparison of thge depth of focus for each condition will be made.

Eligibility criteria:
inclusion criteria: * suitable and able to wear contact lenses * normal best corrected vision (20/25 or better) * need reading add +2.00 or stronger exclusion criteria: * pre-existing ocular condition that would contraindicating lens wear

Keywords: soft contact lens
food-based intervention and psychosocial stimulation to improve growth & development of < 24 month indonesian children

Conditions: Nutritional Anemia; Child Development

Summary: who has urged all developing countries to develop programmes to improve complementary-feeding (cf) practices because of their importance for optimal growth, development and health of infants and young children while supplementation programmes and/or highly-fortified "super-foods" have limited success in improving cf-practices in disadvantaged environments, population-specific food-based dietary guidelines (fbdg), based on locally-available foods and requires minimal changes to local food pattern, will enhance the chances of programme success. our previous study was able to identify the need for, potential and finally develop fbdg for cf of 6-8mo and 9-11mo infants using combined linear-and-goal programming approach (lp approach). this research is therefore being made to support the next phase of the study i.e. to assess the efficacy of fbdg, for improving cf/dietary-practices and growth in \<24mo children (window of opportunity). as growth and development is inter-related, home-based stimulation will be included in this trial to see the effect on child development. while studies have shown that stimulation at early age benefits children through their late adolescence; evidence from indonesia is lacking. this study therefore aims to see the effect on growth and development of community trial using food-based dietary guideline and stimulation. it is expected that findings from this study will provide scientific evidence as the basis for program formulation.


Eligibility criteria:
inclusion criteria: * children aged 9-11 month on enrolment, * weight-for-age z-score \ -3.00 exclusion criteria: * having mental or physical disabilities